Arjo: Arjo can now offer Dawes-Redman CTG analysis to customers in the US

Medical device company Arjo announces that Dawes-Redman CTG Analysis, used for prenatal diagnosis, has received 510(k) clearance from the US Food and Drug Administration (FDA). This is stated in a press release. Arjo's diagnostics business Huntleigh Healthcare has been the exclusive global distributor of the solution for many years and the approval means that it can now also be offered to customers in the US market. Dawes-Redman CTG analysis evaluates factors such as basal heart rate, sinusoidal rhythms and the short-term variation of fetal heart rate, a factor that is impossible to calculate manually.